July 1, 2021 -- Filtration, separation, and purification company Pall has signed a new $7 million contract with contract development and manufacturing organization (CDMO) Exothera.
Under the agreement, Pall will establish a suspension-based manufacturing platform of up to 2,000 L using a variety of technologies including Pall's Allegro single-use bioreactors. The new platform will enable the production of viral vectors for a variety of gene therapies, as well as for vector-based vaccines, the company said.
Exothera selected Pall's end-to-end solution based on its flexibility and capability to scale processes quickly and efficiently, according to Vasily Medvedev, Exothera's head of development. The company will utilize the new platform technology in its new good manufacturing practice (GMP) facilities near Brussels, which are expected to begin production this summer.